Literature DB >> 11023532

The origin of oncogenic mutations: where is the primary damage?

H B Steen1.   

Abstract

Cancer is generally believed to arise from a single cell which has become 'initiated' by mutation of a few crucial genes, caused by random 'hits' in its DNA, a 'hit' being an error in DNA replication or a reaction of the DNA with free radicals or other chemical species of exogenous or endogenous origin. It is not obvious how the epidemiological data on cancer incidence can be interpreted within the framework of this paradigm. For example, it cannot account quantitatively for the age dependence of cancer incidence, or for the fact that the incidence of cancer in people with hereditary mutations in tumour suppressor genes is much lower than expected, or for the observation that while in some types of cancer, like colon and pancreas, certain highly oncogenic mutations, such as that of TP53, are prevalent, there is no significant increase in the incidence of these cancers in people who carry the mutations by heredity. It is argued here that although mutations in such genes appear to be of crucial importance in carcinogenesis they may not be the rate limiting events in common cancer. The epidemiological data are consistent with the hypothesis that the rate limiting processes involve large numbers of cells. Conceivably, the mutations directly underlying neoplastic transformation may be the result of a local collapse in the system of intercellular processes on which the stability of the normal genotype and phenotype depends, and thereby trigger a cascade of mutations, among them the highly oncogenic ones. This local collapse may be due to mutations of many different genes in many cells as well as to other factors affecting the integrity of tissue.

Entities:  

Mesh:

Year:  2000        PMID: 11023532     DOI: 10.1093/carcin/21.10.1773

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

Review 1.  An evolutionary paradigm for carcinogenesis?

Authors:  P Vineis; G Matullo; M Manuguerra
Journal:  J Epidemiol Community Health       Date:  2003-02       Impact factor: 3.710

Review 2.  The duality of human oncoproteins: drivers of cancer and congenital disorders.

Authors:  Pau Castel; Katherine A Rauen; Frank McCormick
Journal:  Nat Rev Cancer       Date:  2020-04-27       Impact factor: 60.716

Review 3.  Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB).

Authors:  Michael Tu; David Chia; Fang Wei; David Wong
Journal:  Analyst       Date:  2016-01-21       Impact factor: 4.616

Review 4.  Road to the crossroads of life and death: linking sister chromatid cohesion and separation to aneuploidy, apoptosis and cancer.

Authors:  Anil K Panigrahi; Debananda Pati
Journal:  Crit Rev Oncol Hematol       Date:  2009-01-21       Impact factor: 6.312

Review 5.  The molecular basis of lung cancer: molecular abnormalities and therapeutic implications.

Authors:  Pierre P Massion; David P Carbone
Journal:  Respir Res       Date:  2003-10-07

6.  Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma.

Authors:  Meeta P Pradhan; Akshay Desai; Mathew J Palakal
Journal:  BMC Syst Biol       Date:  2013-12-26

Review 7.  Remodeling the Microenvironment before Occurrence and Metastasis of Cancer.

Authors:  Xina Zhang; Juanjuan Xiang
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.